Ionis Pharmaceuticals layoffs, on the record
Every job cut, severance charge and restructuring Ionis Pharmaceuticals reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 1,069 to 1,402.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | 1,069 | February 13, 2025 |
| 10-K for 2025 | 1,402 | February 19, 2026 |
Job cuts, severance and restructuring
Our summaryThe company adopted a change of control and severance benefit plan covering executive officers, including the chief executive officer and chief financial officer, and vice presidents.
Word for word“In addition, we implemented a change of control and severance benefit plan that provides for change of control and severance benefits to our executive officers, including our chief executive officer and chief financial officer, and vice presidents.” 10-K for 2023
Our summaryThe company filed an Amended and Restated Severance Benefit Plan dated March 17, 2022 as an exhibit, incorporated by reference.
Word for word“10.2* Registrant’s Amended and Restated Severance Benefit Plan dated March 17, 2022 , filed as an exhibit to the Registrant’s Quarterly Report on form 10-Q for the quarter ended March 31, 2022 and incorporated herein by reference.” 10-K for 2023
Ionis Pharmaceuticals filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Ionis Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.